From: Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Generic name | Mechanism of action | FDA-approved for JIA?* |
---|---|---|
Biologic | ||
Abatacept | T-cell co-stimulation modulator; soluble fusion protein | Yes |
Adalimumab | TNF inhibitor; anti-TNF monoclonal antibody | Yes |
Anakinra | IL-1 receptor antagonist | No |
Canakinumab | IL-1 inhibitor; anti-IL-1beta monoclonal antibody | No |
Etanercept | TNF inhibitor; fusion protein TNF receptor inhibitor, | Yes |
Infliximab | TNF inhibitor; anti-TNF monoclonal chimeric antibody | No |
IVIG | Interaction with activating Fc receptors | No |
Rilonacept | IL-1 inhibitory; soluble fusion protein | No |
Rituximab | Binds to CD20 antigen | No |
Tocilizumab | IL-6 receptor antagonist | No |
Non-Biologic | ||
Azathioprine | Purine synthesis inhibitor | No |
Cyclosporine A | Calcineurin inhibitor | No |
Penicillamine | Unknown (may lower IgM rheumatoid factor, depresses T-cell activity) | No |
Hydroxy-chloroquine | Not well understood, may reduce T-lymphocyte transformation and chemotaxis | No |
Leflunomide | Isoxazole immunomodulatory agent | No |
Methotrexate | Unknown (anti-metabolite, inhibits dihydrofolic acid reductase) | Yes |
Mycophenolate mofetil | Guanosine synthesis inhibitor | No |
Sulfasalazine | Unknown | Yes |
Tacrolimus (FK506) | Calcineurin inhibitor | No |
Thalidomide | Unknown | No |